

DISCLOSURE: The following authors disclosed financial relationships: C. Ma: Consultant for AVIR Pharma Inc and Alimentiv Inc; speaker for AVIR Pharma Inc. A. J. Bredenoord: Research support from Norgine, Nutricia, Thelial, SST, and Bayer; speaker and consultant for AstraZeneca, Medtronic, Laborie, Alimentiv, Celgene, DrFalkPharma, Arena, Esocap, Calypso, and Regeneron. E. S. Dellen: Research support from Adare/Ellodi, Allakos, AstraZeneca, Banner, Holoclara. GlaxoSmithKline, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, and Shire/Takeda; consultant for Abbott, Abbvie, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Landos, Morphic, Parexel/Calyx, Regeneron, Robarts/Alimentiv Inc, Salix, Sanofi, and Shire/Takeda. J. A. Alexander: Received research support from Regeneron, Adare, Arena, Celgene, and Ellode; consultant for Alimentiv; financial interest in Meritage Pharmacia. L. B Biedermann: Consultant and/or Falk Foundation, Vifor AG, Esocap AG, Sanofi-Aventis AG, and Calypso Biotech SA. M. Hogan, L. Guizzetti, J. Rémillard: Employee of Alimentiv Inc. G. Zou, L. M. Shackelton: Consultant for Alimentiv Inc. D. A. Katzka: Consultant for Takeda and Celgene. M. Chehade: Research support from Regeneron, Allakos, Shire, AstraZeneca, and Danone; consultant for Regeneron, Allakos, Adare, Shire/Takeda, AstraZeneca, Sanofi, Ellodi, Phathom, and Bristol Myers Squibb. G. W. Falk: Research support from Adare/Ellodi, Arena, Allakos, Celgene/Receptos/BMS, Lucid, Regeneron, and Shire/Takeda; consultant for Adare/Ellodi, Allakos, Arena, Celgene/Receptos/BMS, Lucid, Regeneron, Sanofi, and Shire/Takeda. G. T. Furuta: Research support from Holoclara and Arena; consultant for Takeda; cofounder of EnteroTrack. S. K. Gupta: Consultant for Abbott, Adare, Allakos, Celgene, Gossamer Bio, QOL, UpToDate, Medscape, and Viaskin; research support from Shire, Allakos, Adare, and National Institutes of Health U54 grant to the Consortium of Eosinophilic Gastrointestinal Disease Researchers. A. M. Schoepfer: Research support from Adare/Ellodi, AstraZeneca, Receptos/BMS, Dr Falk Pharma, Regeneron, and Vifor Pharma; consultant for Adare/Ellodi, Amgen, AstraZeneca, Celgene/Receptos/BMS, Dr Falk Pharma, GlaxoSmithKline, Gossamer Bio, Regeneron, Sanofi-Genzyme, and Vifor Pharma. S. Miehke: Consultant for Dr Falk Pharma, EsoCap, Sanofi-Regeneron, and Celgene; Falk Foundation/Falk Foundation. F. J. Moawad: Consultant for Medtronic, Shire/Takeda, and Sanofi. K. Peterson: Research support from Adare/Ellodi, Allakos, AstraZeneca, Receptos/BMS, Regeneron, Shire/Takeda, and Chobani; consultant for Adare/Ellodi, Allakos, Alladapt, AstraZeneca, Celgene/Receptos/BMS, Regeneron, Sanofi, and Shire/Takeda. N. P. Gonsalves: Consultant for Allakos, Sanofi-Regeneron, Abbvie, Astra-Zeneca, and Nutricia; royalties from Up-to-Date. A. Straumann: Consultant for Allakos, Astra-Zeneca, Calypso, EsoCap, Falk Pharma, Gossamer, Nutricia, Pfizer, Receptos-Celgene, Regeneron-Sanofi, Roche-Genentec, Shire, and Tillotts. J. B. Wechsler: Consultant for Allakos, Regeneron, and Sanofi/Genzyme. B. G. Feagan: Consultant for AbbVie, AdMIRx, AgomAB Therapeutics, Akebia, Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport Inc, Arena Pharma, Avir, Azora Therapeutics, Boehringer-Ingelheim, Boston Pharma, Celgene/BMS, Connect BioPharma, Cytoki, Disc Medicine, Everest Clinical Research Corp, Eli Lilly, Equillium, Ferring, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Glenmark, Gossamer Pharma, GSK, Hoffmann-LaRoche, Hot Spot Therapeutics, Index Pharma, ImmunExt, Imhotex, Intact Therapeutics, Janssen, Japan Tobacco Inc, Kaleido Biosciences, Leadiant, Millennium, MiroBio, Morphic Therapeutics, Mylan, OM Pharma, Origo BioPharma, Otsuka, Pandion Therapeutics, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, PTM Therapeutics, Q32 Bio, Rebiotix, RedHill, Biopharma, REDX, Sandoz, Sanofi, Seres Therapeutics, Surrozen Inc, Takeda, Teva, Thelium, Theravance, Tigenix, Tillotts, UCB Pharma, VHSquared Ltd, Viatrix, Ysios, and Zealand Pharma; Speaker's Bureau for AbbVie, Janssen, and Takeda; Member, Scientific Advisory Board for AbbVie, Amgen, Boehringer-Ingelheim, Celgene/BMS Genentech/Roche, Janssen, Novartis, Origo BioPharma, Pfizer, Prometheus, Takeda, Tillotts Pharma, Teva, Progenity, Index, Ecor1Capital, Morphic, and GSK; stock shareholder in Gossamer Pharma; employee, Western University and Alimentiv Inc. V. Jairath: Consultant for AbbVie, Alimentiv Inc (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, GlaxoSmithKline,

Genetech, Gilead, Janssen, Merck, Mylan, Pendopharm, Pfizer, Roche, Sandoz, Takeda, and Topivert; speaker for Abbvie, Ferring, Janssen Pfizer Shire, and Takeda. I. Hurano: Research support from Adare/Ellodi, Allakos, AstraZeneca, Meritage, Receptos/BMS, Regeneron, and Shire/Takeda; consultant for Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Calypso, Celgene/Receptos/BMS, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Sanofi, and Shire/Takeda. All other authors disclosed no financial relationships.